Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
DNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.78 - $32.27
Previous CloseN/A
Volume29.07K
Average Volume (3M)370.48K
Market Cap
$517.86M
Enterprise Value$656.59M
Total Cash (Recent Filing)$50.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 08, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding32,125,180
10 Day Avg. Volume376,787
30 Day Avg. Volume370,476
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)60.97
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit105.31
Enterprise Value/Ebitda-6.46
Forecast
1Y Price Target
$42.60Price Target Upside164.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Dianthus Therapeutics News
PremiumCompany Announcements
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
Dianthus Therapeutics Appoints Sujay Kango to Board
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityDianthus has $357.0M in cash, cash equivalents, and investments, expected to fund operations into the second half of 2027.
Market OpportunitySales of AstraZeneca’s Ultomiris grew 33%, highlighting the commercial opportunity for complement inhibitors in generalized myasthenia gravis.
Product AdvantageDNTH103 offers a more convenient, low-volume SC administered therapy that patients can inject themselves at home.
Bears Say
Competitive LandscapeDNTH103 offers potential differentiation in each indication vs approved/pipeline competition.
Market SentimentShort interest for Dianthus is at 27.5% of the float.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $14.78 and its highest was $32.27 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $517.86M.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 30 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Mar 11, 2025. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.85 by $0.04.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 32,125,180 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.85. Following the earnings report the stock price went down -6.33%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
---
Dianthus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.60 (164.27% Upside)
$42.60 (164.27% Upside)
Blogger Sentiment
Neutral
DNTH Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 416.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.81%
12-Months-Change
Fundamentals
Return on Equity
-32.60%
Trailing 12-Months
Asset Growth
108.60%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
---
DNTH Stock 12 Month Forecast
Average Price Target
$42.60
▲(164.27% Upside)
Technical Analysis
Best Analysts Covering DNTH
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-25.18%
reiterated a buy rating 28 days ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -25.18% per trade.
---